DoMore Diagnostics announces expansion of the Scientific Advisory Board
Oslo, Norway - DoMore Diagnostics, a leader in deep learning precision diagnostics in digital pathology, is pleased to announce four notable additions to the Scientific Advisory Board (SAB); Dr. Takayuki Yoshino, from the National Cancer Center Hospital (Japan), Professor Hans-Joachim Schmoll, from the University Hospital of Halle (Germany), Professor Jakob Nikolas Kather, from the Technical University of Dresden (Germany) and Professor Marc Peeters, CEO of Antwerp University Hospital (Belgium). All four are major leaders within gastrointestinal (GI) cancer research, development of new technologies and treatments. Their deep understanding and experience will provide vital contributions in bringing our technology forward and making our products available to patients world wide.
“It is a great honor for us in DoMore Diagnostics to work with such highly esteemed and experienced experts in the field of oncology and artificial intelligence. Their input will be highly valuable for the company in our ongoing process of bringing our cutting-edge technology to patients. We wish them a very warm welcome”, said Torbjørn Furuseth, CEO and Co-founder in DoMore Diagnostics.
Dr. Takayuki Yoshino, MD
Dr. Takayuki Yoshino, M.D. PhD. currently works at the National Cancer Center Hospital East (NCCE) in Kashiwa, Japan, where he is the Deputy Director of Hospital, Head, Division for the Promotion of Drug and Diagnostic Development and Director for the Department of Gastrointestinal Oncology.
Dr. Yoshino has had over 300 peer-review scholar journal publications on CRC. In addition, he holds several professional appointments, serving on a Guidelines Steering Committee member of ESMO, a chair of Pan-Asian adapted ESMO Guideline for CRC, an advisory committee member of ASCO Breakthrough, the Vice President of JSCO and the administrative board & a chair of international affairs committee of JSMO. He was the first Japanese plenary speaker at ASCO 2022 Annual Meeting (5th /JUN/ 2022).
Prof. Hans-Joachim Schmoll, MD
Prof. Dr. med. Hans-Joachim Schmoll is currently leading the clinical oncology research at University Hospital of Halle, Germany.
For decades, Professor Schmoll has been a leader within GI oncology, and was one of the key opinion leaders driving the development of modern testicular cancer treatment. He has been very active in the global oncology community with key positions in ESMO, ASCO, and AIO (Germany). He has been a very active researcher and teacher with numerous publications and book contributions.
Prof. Jakob Nikolas Kather, MD
Jakob Nikolas Kather is a physician specializing in gastrointestinal oncology, and an AI researcher with a university degree in the field of biomedical engineering. He holds a professorship of „Clinical AI“ at the Technical University of Dresden in Germany. Together with his research team, he has been among the global pioneers for biomarker detection in computational pathology since 2016. Their research has recently been published in Nature Medicine and Nature Cancer, among other venues, and has led to the development of several AI methods which are approved for clinical use.
Prof. Marc Peeters, MD
Dr. Marc Peeters is CEO of the Antwerp University Hospital and Professor of oncology at the Antwerp University. Until November 2021, he was head of the oncology department at the Antwerp University Hospital and coordinator of the Multidisciplinary Oncology Center Antwerp.
Dr. Peeters is co-chair of the colorectal task force of EORTC.
His research interests have included the identification of molecular markers and therapy modulation in digestive tumors. He has been involved in many clinical studies on therapeutic agents for gastrointestinal tumors, published numerous articles in peer reviewed journals and was author and editor of several chapters in oncology books.